Pfizer ends Covid-19 trial with 95% efficacy, to seek emergency-use authorization

Pfizer Inc said on Wednesday that final results from the late-stage trial of its Covid-19 vaccine show it was 95% effective, adding it had the required two-months of safety data and would apply for emergency US authorization within days. The drugmaker said efficacy of the vaccine developed with German partner BioNTech SE was consistent across age and ethnicity demographics.